Amgen's Biosimilar IP Win Was Wrong, Hospira Tells Fed. Circ.
Hospira has urged the Federal Circuit to toss a $70 million jury verdict finding its biosimilar version of Amgen Inc.'s blockbuster anemia treatment Epogen infringed an Amgen patent, arguing its drug...To view the full article, register now.
Already a subscriber? Click here to view full article